An increase of CD4+CD25 + cells and CD4+CD25 + FoxP3+ Treg cells in peripheral blood after DD for rituximab has been described in a successful procedure in a patient suffering from nephrotic syndrome (Aydogan et al., 2013). This evidence concerns the gene CD4 and nephrotic syndrome.